Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD

CompletedOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
LRG Levels
Interventions
DIAGNOSTIC_TEST

serum leucine-rich alpha-2 glycoprotein (LRG) levels

Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.

Trial Locations (1)

399-4117

Showa Inan General Hospital, Komagane

All Listed Sponsors
lead

Showa Inan General Hospital

OTHER

NCT04535882 - Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD | Biotech Hunter | Biotech Hunter